Latest Skin News
Drug Approved for Treatment of Postherpetic Neuralgia (PHN)
By Jennifer Warner
WebMD Health News
Reviewed by Laura J. Martin, MD
Researchers say about 1 million people in the U.S. develop shingles each year. Of these, about 10% will go on to develop PHN.
New Use for Drug
Horizant was approved in 2011 to treat restless leg syndrome.
In approving Horizant to treat PHN, the FDA evaluated the safety and effectiveness of the drug in three clinical trials involving 574 people.
The drug may also impair a person's ability to drive a car. People taking Horizant should not drive a car or operate heavy machinery until they have enough experience with the drug to determine whether their driving ability is affected.
Horizant is a slightly less active form of the antiepileptic drug gabapentin. This type of antiepileptic drug increases the risk of suicidal thoughts and behaviors.
The drug was developed by XenoPort Inc. and is marketed by GlaxoSmithKline.
Health Solutions From Our Sponsors
©2012 WebMD, LLC. All Rights Reserved.